(Total Views: 696)
Posted On: 02/24/2025 5:27:14 PM
Post# of 154868
Jeff: Re "pre-clinical trials" for mTNBC, I had the same initial reaction. But I quickly realized that Dr J is certainly not steering CYDY or LL in reverse with a redundant mouse study. As we all try to puzzle out the game plan going forward, I think it is worth remembering that we are constantly hampered by not knowing what we don't know.
The news that some of the original 28 mTNBC patients treated with LL are still alive and cancer free since the trial ended (and treatment with LL presumably stopped) in August, 2021, is astonishing. Consequently, I think we can count on the fact that Dr Jay and Dr Pestell have very good reasons to engage SMC Labs for a mouse study that combines LL with Keytruda and a Gilead drug, Trodelvy.
Plotinus has already posted with a very plausible explanation for conducting this study. Moreover, keeping in mind that mouse studies take only a few months, another plausible possibility might be that Merck (or even Gilead), acting pursuant to a NDA, has requested that some discrete attribute of LL's efficacy or MOA be more rigorously examined as a prelude to a major deal.
Ohm probably could point out several other plausible explanations, but even he is hampered by not knowing what he doesn't know. Nevertheless, we can all sleep soundly tonight confident in the knowledge that there is a very sound reason for this planned mouse study, and that the CYDY ship continues to gather considerable steam, with a very talented team at the helm.
I haven't been this excited about the future of CYDY and LL since the days before the botched covid12 trial were announced in Feb, 2021.
Good luck to all.
The news that some of the original 28 mTNBC patients treated with LL are still alive and cancer free since the trial ended (and treatment with LL presumably stopped) in August, 2021, is astonishing. Consequently, I think we can count on the fact that Dr Jay and Dr Pestell have very good reasons to engage SMC Labs for a mouse study that combines LL with Keytruda and a Gilead drug, Trodelvy.
Plotinus has already posted with a very plausible explanation for conducting this study. Moreover, keeping in mind that mouse studies take only a few months, another plausible possibility might be that Merck (or even Gilead), acting pursuant to a NDA, has requested that some discrete attribute of LL's efficacy or MOA be more rigorously examined as a prelude to a major deal.
Ohm probably could point out several other plausible explanations, but even he is hampered by not knowing what he doesn't know. Nevertheless, we can all sleep soundly tonight confident in the knowledge that there is a very sound reason for this planned mouse study, and that the CYDY ship continues to gather considerable steam, with a very talented team at the helm.
I haven't been this excited about the future of CYDY and LL since the days before the botched covid12 trial were announced in Feb, 2021.
Good luck to all.
(27)
(0)
